NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/18/2026 12:55
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization14,099 mln
Float181 mln
Earnings Date11/03/2026
EPS
3.18
Solid
P / E
18.25
Moderately valued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-3.04
Reliable
1-Year Forecast
53.69
Limited downside
Relative Strength
48
/ 100
In line with market
Business Description
Exelixis is a US-based cancer medicine company that develops and sells treatments for hard-to-treat cancers. Its main products are cabozantinib-based drugs, marketed as CABOMETYX and COMETRIQ, which are used to treat advanced kidney cancer and a rare form of thyroid cancer, respectively. The company also has a growing pipeline of experimental drugs targeting various cancers, and works alongside several major pharmaceutical partners to advance its research. Founded in 1994 and based in Alameda, California, Exelixis continues to expand its reach in oncology through both internal development and external collaborations.
